Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Apr 1;99(7):1467–1471. doi: 10.1172/JCI119307

Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.

B S Coller 1
PMCID: PMC507964  PMID: 9119988

Full Text

The Full Text of this article is available as a PDF (105.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ammar T., Scudder L. E., Coller B. S. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation. 1997 Feb 4;95(3):614–617. doi: 10.1161/01.cir.95.3.614. [DOI] [PubMed] [Google Scholar]
  2. Barrett J. S., Murphy G., Peerlinck K., De Lepeleire I., Gould R. J., Panebianco D., Hand E., Deckmyn H., Vermylen J., Arnout J. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther. 1994 Oct;56(4):377–388. doi: 10.1038/clpt.1994.152. [DOI] [PubMed] [Google Scholar]
  3. Coller B. S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995 Nov 1;92(9):2373–2380. doi: 10.1161/01.cir.92.9.2373. [DOI] [PubMed] [Google Scholar]
  4. Coller B. S., Folts J. D., Scudder L. E., Smith S. R. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood. 1986 Sep;68(3):783–786. [PubMed] [Google Scholar]
  5. Coller B. S. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood. 1980 Feb;55(2):169–178. [PubMed] [Google Scholar]
  6. Coller B. S., Kutok J. L., Scudder L. E., Galanakis D. K., West S. M., Rudomen G. S., Springer K. T. Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen. J Clin Invest. 1993 Dec;92(6):2796–2806. doi: 10.1172/JCI116899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Coller B. S. Platelets and thrombolytic therapy. N Engl J Med. 1990 Jan 4;322(1):33–42. doi: 10.1056/NEJM199001043220107. [DOI] [PubMed] [Google Scholar]
  8. Coller B. S., Seligsohn U., Peretz H., Newman P. J. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol. 1994 Oct;31(4):301–311. [PubMed] [Google Scholar]
  9. Diacovo T. G., Roth S. J., Buccola J. M., Bainton D. F., Springer T. A. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood. 1996 Jul 1;88(1):146–157. [PubMed] [Google Scholar]
  10. Goldsmith H. L., Turitto V. T. Rheological aspects of thrombosis and haemostasis: basic principles and applications. ICTH-Report--Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis. Thromb Haemost. 1986 Jun 30;55(3):415–435. [PubMed] [Google Scholar]
  11. Groves H. M., Kinlough-Rathbone R. L., Mustard J. F. Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Arteriosclerosis. 1986 Mar-Apr;6(2):189–195. doi: 10.1161/01.atv.6.2.189. [DOI] [PubMed] [Google Scholar]
  12. Harrington R. A., Kleiman N. S., Kottke-Marchant K., Lincoff A. M., Tcheng J. E., Sigmon K. N., Joseph D., Rios G., Trainor K., Rose D. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995 Dec 15;76(17):1222–1227. doi: 10.1016/s0002-9149(99)80345-2. [DOI] [PubMed] [Google Scholar]
  13. Lefkovits J., Plow E. F., Topol E. J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995 Jun 8;332(23):1553–1559. doi: 10.1056/NEJM199506083322306. [DOI] [PubMed] [Google Scholar]
  14. Marcus A. J., Safier L. B., Broekman M. J., Islam N., Fliessbach J. H., Hajjar K. A., Kaminski W. E., Jendraschak E., Silverstein R. L., von Schacky C. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Thromb Haemost. 1995 Jul;74(1):213–217. [PubMed] [Google Scholar]
  15. Matsuno H., Stassen J. M., Vermylen J., Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994 Nov;90(5):2203–2206. doi: 10.1161/01.cir.90.5.2203. [DOI] [PubMed] [Google Scholar]
  16. Moliterno D. J., Califf R. M., Aguirre F. V., Anderson K., Sigmon K. N., Weisman H. F., Topol E. J. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol. 1995 Mar 15;75(8):559–562. doi: 10.1016/s0002-9149(99)80616-x. [DOI] [PubMed] [Google Scholar]
  17. Olshansky S. J., Ault A. B. The fourth stage of the epidemiologic transition: the age of delayed degenerative diseases. Milbank Q. 1986;64(3):355–391. [PubMed] [Google Scholar]
  18. Reverter J. C., Béguin S., Kessels H., Kumar R., Hemker H. C., Coller B. S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest. 1996 Aug 1;98(3):863–874. doi: 10.1172/JCI118859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Savage B., Saldívar E., Ruggeri Z. M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996 Jan 26;84(2):289–297. doi: 10.1016/s0092-8674(00)80983-6. [DOI] [PubMed] [Google Scholar]
  20. Thiruvikraman S. V., Guha A., Roboz J., Taubman M. B., Nemerson Y., Fallon J. T. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest. 1996 Oct;75(4):451–461. [PubMed] [Google Scholar]
  21. Topol E. J., Califf R. M., Weisman H. F., Ellis S. G., Tcheng J. E., Worley S., Ivanhoe R., George B. S., Fintel D., Weston M. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet. 1994 Apr 9;343(8902):881–886. doi: 10.1016/s0140-6736(94)90007-8. [DOI] [PubMed] [Google Scholar]
  22. Wilentz J. R., Sanborn T. A., Haudenschild C. C., Valeri C. R., Ryan T. J., Faxon D. P. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation. 1987 Mar;75(3):636–642. doi: 10.1161/01.cir.75.3.636. [DOI] [PubMed] [Google Scholar]
  23. Zaidi T. N., McIntire L. V., Farrell D. H., Thiagarajan P. Adhesion of platelets to surface-bound fibrinogen under flow. Blood. 1996 Oct 15;88(8):2967–2972. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES